New test aims to stop unnecessary antibiotics for respiratory infections
NCT ID NCT06070688
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new diagnostic tool that helps doctors quickly tell if a respiratory infection is caused by bacteria or a virus. The goal is to see if using this test leads to better treatment decisions, fewer unnecessary antibiotics, and lower healthcare costs. About 100 adults with early symptoms of a respiratory infection will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for main study population : * Current disease duration ≤ 7 days * Temperature ≥ 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days * Clinical suspicion of bacterial or viral respiratory tract infection (RTI) Exclusion Criteria for main study population: * Systemic antibiotics taken up to 48 hours prior to presentation * Outpatient steroids taken within 48 hours prior to presentation * Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis * Inflammatory disease * Congenital immune deficiency (CID) * A proven or suspected infection on the presentation with Mycobacterial, parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen * Human immunodeficiency virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (self-declared or known from medical records) * Major trauma and/or burns in the last 7 days * Major surgery in the last 7 days * Pregnancy - Self reported or medically confirmed * Active malignancy - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission. * Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days * Hemodynamically unstable (require life-saving interventions such as vasopressors) * Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results) * Consider unsuitable for the study by the study team Inclusion Criteria for Subgroup: * Written informed consent must be obtained from the patient or his/her legal guardian * Current disease duration ≤ 7 days * Clinical suspicion of bacterial or viral sepsis based on 2 or more SIRS criteria OR Clinical suspicion of bacterial or viral respiratory tract infection (RTI) AND temperature ≥ 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days Patients fulfilling one or more of the following exclusion criteria from the main group are eligible for the subgroup cohort: * Systemic antibiotics taken up to 48 hours prior to presentation * Outpatient steroids taken within 48 hours prior to presentation * Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis * Inflammatory disease (e.g., IBD, SLE, RA, other vasculitis) * Congenital immune deficiency (CID) * A proven or suspected infection on the presentation with Mycobacterial (e.g., MAC, MABC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen * HIV, HBV, or HCV infection (self-declared or known from medical records) * Major trauma and/or burns in the last 7 days * Major surgery in the last 7 days * Pregnancy - Self reported or medically confirmed * Active malignancy of a solid tumor - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission * Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days * Hemodynamically unstable (require life-saving interventions such as vasopressors) * Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Respiratory tract infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The University of Texas Health Science Center at Houston
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose to block the flu: baloxavir put to the test in households
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- New AI-Powered swab test aims to spot viruses in minutes
- AI stethoscope aims to cut unnecessary antibiotics in kids with cough
- Placenta cells tested as COVID fighter – but trial stopped early
- RSV study seeks immune clues in older adults